

PATENT NUMBER

## U.S. UTILITY Patent Application

**O.I.P.E.**

PATENT DATE

SCANNED

11. 11. 74 Q.A.

APPLICATION NO. 09/988285	CONT/PRIOR D F	CLASS 514	SUBCLASS 2	ART UNIT 1634	EXAMINER J. J. J.
------------------------------	-------------------	--------------	---------------	------------------	----------------------

TITLE	APPLICANTS
1. <b>Chairman</b>	1. <b>Chairman</b>
2. <b>Vice Chairman</b>	2. <b>Vice Chairman</b>
3. <b>Secretary</b>	3. <b>Secretary</b>
4. <b>Treasurer</b>	4. <b>Treasurer</b>
5. <b>Member</b>	5. <b>Member</b>
6. <b>Member</b>	6. <b>Member</b>
7. <b>Member</b>	7. <b>Member</b>
8. <b>Member</b>	8. <b>Member</b>
9. <b>Member</b>	9. <b>Member</b>
10. <b>Member</b>	10. <b>Member</b>
11. <b>Member</b>	11. <b>Member</b>
12. <b>Member</b>	12. <b>Member</b>
13. <b>Member</b>	13. <b>Member</b>
14. <b>Member</b>	14. <b>Member</b>
15. <b>Member</b>	15. <b>Member</b>
16. <b>Member</b>	16. <b>Member</b>
17. <b>Member</b>	17. <b>Member</b>
18. <b>Member</b>	18. <b>Member</b>
19. <b>Member</b>	19. <b>Member</b>
20. <b>Member</b>	20. <b>Member</b>
21. <b>Member</b>	21. <b>Member</b>
22. <b>Member</b>	22. <b>Member</b>
23. <b>Member</b>	23. <b>Member</b>
24. <b>Member</b>	24. <b>Member</b>
25. <b>Member</b>	25. <b>Member</b>
26. <b>Member</b>	26. <b>Member</b>
27. <b>Member</b>	27. <b>Member</b>
28. <b>Member</b>	28. <b>Member</b>
29. <b>Member</b>	29. <b>Member</b>
30. <b>Member</b>	30. <b>Member</b>
31. <b>Member</b>	31. <b>Member</b>
32. <b>Member</b>	32. <b>Member</b>
33. <b>Member</b>	33. <b>Member</b>
34. <b>Member</b>	34. <b>Member</b>
35. <b>Member</b>	35. <b>Member</b>
36. <b>Member</b>	36. <b>Member</b>
37. <b>Member</b>	37. <b>Member</b>
38. <b>Member</b>	38. <b>Member</b>
39. <b>Member</b>	39. <b>Member</b>
40. <b>Member</b>	40. <b>Member</b>
41. <b>Member</b>	41. <b>Member</b>
42. <b>Member</b>	42. <b>Member</b>
43. <b>Member</b>	43. <b>Member</b>
44. <b>Member</b>	44. <b>Member</b>
45. <b>Member</b>	45. <b>Member</b>
46. <b>Member</b>	46. <b>Member</b>
47. <b>Member</b>	47. <b>Member</b>
48. <b>Member</b>	48. <b>Member</b>
49. <b>Member</b>	49. <b>Member</b>
50. <b>Member</b>	50. <b>Member</b>
51. <b>Member</b>	51. <b>Member</b>
52. <b>Member</b>	52. <b>Member</b>
53. <b>Member</b>	53. <b>Member</b>
54. <b>Member</b>	54. <b>Member</b>
55. <b>Member</b>	55. <b>Member</b>
56. <b>Member</b>	56. <b>Member</b>
57. <b>Member</b>	57. <b>Member</b>
58. <b>Member</b>	58. <b>Member</b>
59. <b>Member</b>	59. <b>Member</b>
60. <b>Member</b>	60. <b>Member</b>
61. <b>Member</b>	61. <b>Member</b>
62. <b>Member</b>	62. <b>Member</b>
63. <b>Member</b>	63. <b>Member</b>
64. <b>Member</b>	64. <b>Member</b>
65. <b>Member</b>	65. <b>Member</b>
66. <b>Member</b>	66. <b>Member</b>
67. <b>Member</b>	67. <b>Member</b>
68. <b>Member</b>	68. <b>Member</b>
69. <b>Member</b>	69. <b>Member</b>
70. <b>Member</b>	70. <b>Member</b>
71. <b>Member</b>	71. <b>Member</b>
72. <b>Member</b>	72. <b>Member</b>
73. <b>Member</b>	73. <b>Member</b>
74. <b>Member</b>	74. <b>Member</b>
75. <b>Member</b>	75. <b>Member</b>
76. <b>Member</b>	76. <b>Member</b>
77. <b>Member</b>	77. <b>Member</b>
78. <b>Member</b>	78. <b>Member</b>
79. <b>Member</b>	79. <b>Member</b>
80. <b>Member</b>	80. <b>Member</b>
81. <b>Member</b>	81. <b>Member</b>
82. <b>Member</b>	82. <b>Member</b>
83. <b>Member</b>	83. <b>Member</b>
84. <b>Member</b>	84. <b>Member</b>
85. <b>Member</b>	85. <b>Member</b>
86. <b>Member</b>	86. <b>Member</b>
87. <b>Member</b>	87. <b>Member</b>
88. <b>Member</b>	88. <b>Member</b>
89. <b>Member</b>	89. <b>Member</b>
90. <b>Member</b>	90. <b>Member</b>
91. <b>Member</b>	91. <b>Member</b>
92. <b>Member</b>	92. <b>Member</b>
93. <b>Member</b>	93. <b>Member</b>
94. <b>Member</b>	94. <b>Member</b>
95. <b>Member</b>	95. <b>Member</b>
96. <b>Member</b>	96. <b>Member</b>
97. <b>Member</b>	97. <b>Member</b>
98. <b>Member</b>	98. <b>Member</b>
99. <b>Member</b>	99. <b>Member</b>
100. <b>Member</b>	100. <b>Member</b>

Johannes Schalliers  
Alfred Schinzel

Method of improving bioavailability of orally administered drugs, a method of screening for enhancers of such bioavailability and novel pharmaceutical compositions for oral delivery of drugs

PTO-2040  
12/99

**ISSUING CLASSIFICATION**

[illegible]

<input type="checkbox"/> <b>TERMINAL DISCLAIMER</b>	<b>DRAWINGS</b>			<b>CLAIMS ALLOWED</b>	
	Sheets Drwg.	Figs. Drwg.	Print Fig.	Total Claims	Print Claim for O.G.
The term of this patent subsequent to _____ (date) has been disclaimed.	_____ (Assistant Examiner) (Date)			<b>NOTICE OF ALLOWANCE MAILED</b>  	
The term of this patent shall not extend beyond the expiration date of U.S Patent. No. _____  	_____ (Primary Examiner) (Date)			<b>ISSUE FEE</b> Amount Due      Date Paid	
The terminal _____ months of this patent have been disclaimed.	_____ <small>*Legal Instruments Examiner*</small> <small>*Date*</small>			<b>ISSUE BATCH NUMBER</b>	
<b>WARNING:</b> The information disclosed herein may be restricted. Unauthorized disclosure may be prohibited by the United States Code Title 35, Sections 122, 181 and 368. Possession outside the U.S. Patent & Trademark Office is restricted to authorized employees and contractors only.					

Form PTO-436A  
(Rev. 6/99)

FILED WITH: ☐ DISK (CRF) ☐ FICHE ☐ CD-ROM

Attached in pocket on right inside flap.